Remifentanil Target Controlled Infusion Versus Standard of Care for Conscious Sedation During EBUS-TBNA
Lung Cancer, Lung; Node, Sedation Complication
About this trial
This is an interventional supportive care trial for Lung Cancer focused on measuring endobronchial ultrasound, mediastinal staging of lung cancer, sedation in endoscopic procedures
Eligibility Criteria
Inclusion Criteria: patients aged 18-80 years, clinical fit to undergo the planned procedure, according to the American Society of Anesthesiologists physical status classification. Exclusion Criteria: current chronic opioid treatment, substance abuse or drug use; pregnancy, history of allergy to related medications; severe coagulation dysfunction; severe hepatic renal dysfunction; history of abnormal recovery from anesthesia; acute respiratory failure; inability or unwillingness to provide informed consent.
Sites / Locations
- Università Campus Bio Medico
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group 1 "REMIFENTANIL TCI" (Experimental Group)
Group 2 "STANDARD" (Control Group)
the patients performed the EBUS-TBNA procedure under conscious sedation with infusion of Remifentanil TCI with a target between 3 and 6 ng/ml;
the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement.